Clinical Significance of Peripheral Blood-derived Inflammation Markers in Advanced Gastric Cancer After Radical Resection

Overview

Journal BMC Surg

Publisher Biomed Central

Specialty General Surgery

Date 2020 Oct 3

PMID 33008382

Citations 19

Authors

Lihu Gu

Mian Wang

Xuena Cui

Jiahang Mo

Lingling Yuan

Feiyan Mao

Kang Zhang

Derry Minyao Ng

Ping Chen

Dongjie Wang

Affiliations

Soon will be listed here.

Abstract

Background: The prognostic significance of peripheral blood-derived inflammation markers in patients with gastric cancer (GC) has not been elucidated. This study aimed to investigate the relationship between systemic inflammatory markers and GC prognosis.

Methods: A prospective observational cohort study involving 598 patients was conducted to analyze the prognosis of GC based on systemic inflammatory markers. The following peripheral blood-derived inflammation markers were evaluated: the neutrophil-lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), systemic immune-inflammation index (SII), C-reactive protein/albumin (CRP/Alb) ratio, Glasgow Prognostic Score (GPS), modified Glasgow Prognostic Score (mGPS), prognostic nutrition index (PNI), and prognostic index (PI). The receiver operating characteristics (ROC) curve and the Youden index were used to determine the optimal cutoff values. Univariate and multivariate analysis of prognostic factors was conducted accordingly.

Results: The optimal cutoff values of the PNI, fibrinogen, NLR, PLR, SII, and CRP/Alb were 49.5, 397 ng/dl, 2.5, 154, 556, and 0.05, respectively. Multivariate analysis showed that age, PLR, TNM stage, and chemotherapy were the independent prognostic factors for advanced gastric cancer (AGC). Adjuvant chemotherapy improved the long-term prognosis of patients with PLR ≥154, but chemotherapy had no significant effect on the survival of patients with PLR < 154.

Conclusions: Our findings show that higher PLR (≥154) is an independent risk factor for poor prognosis in GC patients. Besides, PLR can predict adjuvant chemotherapy (oxaliplatin/5-fluorouracil combination) response in patients with GC after surgery.

Citing Articles

Harnessing the prognostic power of preoperative systemic immune-inflammation index/albumin ratio in hepatocellular carcinoma resection.

Zhang Z, Hao L, Han S, Li S, Lin S, Miao Y World J Gastrointest Surg. 2025; 17(2):102261.

PMID: 40061974 PMC: 11886000. DOI: 10.4240/wjgs.v17.i2.102261.

CRP to Albumin Ratio as a Prognostic Nutrition-Based Biomarker for Patients With Gastric Cancer: A Narrative Review.

Christodoulidis G, Voutyras A, Fotakopoulos G, Koumarelas K, Georgakopoulou V, Kouliou M Cureus. 2024; 16(10):e71516.

PMID: 39553069 PMC: 11563776. DOI: 10.7759/cureus.71516.

Combined systemic inflammatory immune index and prognostic nutrition index as chemosensitivity and prognostic markers for locally advanced gastric cancer receiving neoadjuvant chemotherapy: a retrospective study.

Ding P, Yang J, Wu J, Wu H, Sun C, Chen S BMC Cancer. 2024; 24(1):1014.

PMID: 39148031 PMC: 11328362. DOI: 10.1186/s12885-024-12771-z.

The Systemic Immune-inflammation Index Is an Independent Prognostic Factor for Gastric Cancer Patients Who Receive Curative Treatment.

Aoyama T, Maezawa Y, Hashimoto I, Yamamoto S, Esashi R, Hara K In Vivo. 2024; 38(4):2001-2008.

PMID: 38936948 PMC: 11215563. DOI: 10.21873/invivo.13657.

Systemic immune inflammation index and gastric cancer prognosis: A systematic review and meta‑analysis.

Yang X, Wu C Exp Ther Med. 2024; 27(3):122.

PMID: 38410191 PMC: 10895464. DOI: 10.3892/etm.2024.12410.

References

Koizumi W, Takiuchi H, Yamada Y, Boku N, Fuse N, Muro K . Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol. 2009; 21(5):1001-5. DOI: 10.1093/annonc/mdp464. View

Song S, Li C, Li S, Gao H, Lan X, Xue Y . Derived neutrophil to lymphocyte ratio and monocyte to lymphocyte ratio may be better biomarkers for predicting overall survival of patients with advanced gastric cancer. Onco Targets Ther. 2017; 10:3145-3154. PMC: 5495088. DOI: 10.2147/OTT.S138039. View

Lou N, Zhang L, Chen X, Pang W, Arvine C, Huang Y . A novel scoring system associating with preoperative platelet/lymphocyte and clinicopathologic features to predict lymph node metastasis in early gastric cancer. J Surg Res. 2016; 209:153-161. DOI: 10.1016/j.jss.2016.10.011. View

Liu X, Sun X, Liu J, Kong P, Chen S, Zhan Y . Preoperative C-Reactive Protein/Albumin Ratio Predicts Prognosis of Patients after Curative Resection for Gastric Cancer. Transl Oncol. 2015; 8(4):339-45. PMC: 4562973. DOI: 10.1016/j.tranon.2015.06.006. View

Nora I, Shridhar R, Huston J, Meredith K . The accuracy of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as a marker for gastrointestinal malignancies. J Gastrointest Oncol. 2018; 9(5):972-978. PMC: 6219984. DOI: 10.21037/jgo.2018.08.05. View

Kulig J, Sierzega M, Kolodziejczyk P, Popiela T . Ratio of metastatic to resected lymph nodes for prediction of survival in patients with inadequately staged gastric cancer. Br J Surg. 2009; 96(8):910-8. DOI: 10.1002/bjs.6653. View

Yu L, Lv C, Yuan A, Chen W, Wu A . Significance of the preoperative neutrophil-to-lymphocyte ratio in the prognosis of patients with gastric cancer. World J Gastroenterol. 2015; 21(20):6280-6. PMC: 4445105. DOI: 10.3748/wjg.v21.i20.6280. View

Miyatani K, Saito H, Kono Y, Murakami Y, Kuroda H, Matsunaga T . Combined analysis of the pre- and postoperative neutrophil-lymphocyte ratio predicts the outcomes of patients with gastric cancer. Surg Today. 2017; 48(3):300-307. DOI: 10.1007/s00595-017-1587-6. View

Boku N, Ryu M, Kato K, Chung H, Minashi K, Lee K . Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II.... Ann Oncol. 2018; 30(2):250-258. PMC: 6386029. DOI: 10.1093/annonc/mdy540. View

10.

Rao S, Starling N, Cunningham D, Sumpter K, Gilligan D, Ruhstaller T . Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol. 2010; 21(11):2213-2219. DOI: 10.1093/annonc/mdq247. View

11.

Hu D, Zhang H, Lin X, Chen G, Li C, Liang B . Elevated preoperative neutrophil-to-lymphocyte ratio can predict poor survival in early stage gastric cancer patients receiving radical gastrectomy: The Fujian prospective investigation of cancer (FIESTA) study. J Cancer. 2017; 8(7):1214-1222. PMC: 5463436. DOI: 10.7150/jca.18707. View

12.

Ryu M, Yoo C, Kim J, Ryoo B, Park Y, Park S . Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur J Cancer. 2015; 51(4):482-488. DOI: 10.1016/j.ejca.2014.12.015. View

13.

Lee S, Oh S, Kim S, Lee J, Kim M, Kim K . Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer. 2013; 13:350. PMC: 3729814. DOI: 10.1186/1471-2407-13-350. View

14.

Petrillo A, Laterza M, Tirino G, Pompella L, Ventriglia J, Pappalardo A . Systemic-inflammation-based score can predict prognosis in metastatic gastric cancer patients before first-line chemotherapy. Future Oncol. 2018; 14(24):2493-2505. DOI: 10.2217/fon-2018-0167. View

15.

Hirahara T, Arigami T, Yanagita S, Matsushita D, Uchikado Y, Kita Y . Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer. BMC Cancer. 2019; 19(1):672. PMC: 6615151. DOI: 10.1186/s12885-019-5903-y. View

16.

Park S, Lee S, Song J, Choi S, Cho M, Kwon I . Prognostic significance of body mass index and prognostic nutritional index in stage II/III gastric cancer. Eur J Surg Oncol. 2019; 46(4 Pt A):620-625. DOI: 10.1016/j.ejso.2019.10.024. View

17.

Li J, Xu R, Hu D, Zhang Y, Gong T, Wu X . Prognostic Nutritional Index Predicts Outcomes of Patients after Gastrectomy for Cancer: A Systematic Review and Meta-Analysis of Nonrandomized Studies. Nutr Cancer. 2019; 71(4):557-568. DOI: 10.1080/01635581.2019.1577986. View

18.

. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2016; 20(1):1-19. PMC: 5215069. DOI: 10.1007/s10120-016-0622-4. View

19.

Huang Z, Liu Y, Yang C, Li X, Pan C, Rao J . Combined neutrophil/platelet/lymphocyte/differentiation score predicts chemosensitivity in advanced gastric cancer. BMC Cancer. 2018; 18(1):515. PMC: 5932840. DOI: 10.1186/s12885-018-4414-6. View

20.

Lee H, Hyung W, Yang H, Han S, Park Y, An J . Short-term Outcomes of a Multicenter Randomized Controlled Trial Comparing Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy to Open Distal Gastrectomy for Locally Advanced Gastric Cancer (KLASS-02-RCT). Ann Surg. 2019; 270(6):983-991. DOI: 10.1097/SLA.0000000000003217. View